Chua W, Law JP, Cardoso VR, et al. - As per recent findings, the most suitable biomarkers, identified using an experimental semi-quantitative biomarker assay, for detecting atrial fibrillation (AF) are B-type natriuretic peptide (BNP) and fibroblast growth factor 23 (FGF23) together with simple morphometric parameters (age, gender, and body mass index [BMI]), therefore, researchers sought to validate the AF model employing standardised, high-throughput, high-sensitivity biomarker assays. Participants were 1,625 patients with either diagnosed AF or sinus rhythm with CHA₂DS₂-VASc score of 2 or more. A high-throughput, high-sensitivity assay for FGF23 was constructed, plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) and FGF23 were quantified, and results were compared with the previously employed multibiomarker research assay. In 1,084 patients, higher levels of NT-proBNP and FGF23 were detected in AF patients. A C-statistic of 0.688 was afforded by the fitted model, which was almost identical to that of the derived model (C-statistic 0.691). Based on the findings, experts inferred that a reliable identification of AF cases is afforded by age, gender, and BMI combined with increased NT-proBNP and increased FGF23, quantified on a high-throughput platform.